Filter Results:
(21)
Show Results For
- All HBS Web (43)
- Faculty Publications (7)
Show Results For
- All HBS Web (43)
- Faculty Publications (7)
Page 1 of 21
Results →
Sort by
- September 2013 (Revised August 2014)
- Case
Claritas Genomics
By: Robert F. Higgins and Matthew Preble
Claritas Genomics was formed in January 2013 when BCH spun out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new... View Details
Keywords: Boston Children's Hospital; Genetic Engineering; Genetically Modified; Genetics Diagnostics; Health Care Industry; Healthcare IT; Healthcare Technology; Healthcare Ventures; Biomedical Research; Patrice Milos; Genomics; Genomic Testing; Life Technologies; Health Care and Treatment; Information Technology; Information Management; Genetics; Biotechnology Industry; Information Technology Industry; Health Industry; Boston; Massachusetts; United States
Higgins, Robert F., and Matthew Preble. "Claritas Genomics." Harvard Business School Case 814-032, September 2013. (Revised August 2014.)
- November 2014
- Teaching Note
Claritas Genomics
By: Robert F. Higgins and Matthew G. Preble
Dr. Patrice Milos is the first CEO of Claritas Genomics (Claritas) and she faces a number of challenges in scaling the young company. Claritas was formed around a lab spun out from Boston Children's Hospital (BCH) which had performed genomic tests for the hospital. Now... View Details
- October 2008
- Case
Diagnostic Genomics
By: Regina E. Herzlinger and Mark P. Allyn
Should this gene detection firm enter the business of providing tests for the detection of genetic diseases? If so, how should it prioritize the tests it could develop? View Details
Keywords: Health Testing and Trials; Market Entry and Exit; Product Development; Genetics; Strategy; Health Industry; Medical Devices and Supplies Industry
Herzlinger, Regina E., and Mark P. Allyn. "Diagnostic Genomics." Harvard Business School Case 309-040, October 2008.
- January 2014 (Revised June 2014)
- Case
23andMe: Genetic Testing for Consumers (A)
By: John A. Quelch and Margaret L. Rodriguez
On November 22, 2013, the direct-to-consumer genetic testing provider, 23andMe, received a letter from the U.S. Food and Drug Administration (FDA) ordering the company to halt the sale and promotion of its genetic testing kit. The FDA stated that the product was... View Details
Keywords: Public Health; Genome Testing; Health Care; Ancestry; 23andMe; Marketing; Product Launch; Health; Health Care and Treatment; Health Testing and Trials; Genetics; Strategy; Health Industry; United States
Quelch, John A., and Margaret L. Rodriguez. "23andMe: Genetic Testing for Consumers (A)." Harvard Business School Case 514-086, January 2014. (Revised June 2014.)
- January 2014 (Revised December 2014)
- Case
GenapSys: Business Models for the Genome
By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble
GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details
Keywords: DNA Sequencing; Life Sciences; Business Model; Innovation & Entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Biotechnology Industry; Pharmaceutical Industry; Technology Industry; Health Industry; Medical Devices and Supplies Industry; United States
Hamermesh, Richard G., Joseph B. Fuller, and Matthew Preble. "GenapSys: Business Models for the Genome." Harvard Business School Case 814-050, January 2014. (Revised December 2014.)
- May 2009 (Revised August 2013)
- Case
The DiagnoFirst Opportunity
By: Robert C. Pozen and Rukmini Balu
John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a genetic test that identified a subset of prostate cancer patients with a high risk of clinical... View Details
Keywords: Genetic Engineering; Genetically Modified; Genomics; Venture Capital; Patents; Genetics; Decision Choices and Conditions; Laws and Statutes; Investment; Science-Based Business; Biotechnology Industry
Pozen, Robert C., and Rukmini Balu. "The DiagnoFirst Opportunity." Harvard Business School Case 309-112, May 2009. (Revised August 2013.)
- September 2017 (Revised February 2023)
- Case
Intermountain Healthcare: Pursuing Precision Medicine
By: Richard G. Hamermesh, Kathy E. Giusti, Robert S. Huckman and Julia Kelley
Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment... View Details
Keywords: Precision Medicine; Healthcare; Innovation; Cancer; Cancer Research; Health Care; Technology; Health Care and Treatment; Innovation Leadership; Disruptive Innovation; Entrepreneurship; Decision Choices and Conditions; Health Industry; Insurance Industry; Utah; United States; North America
Hamermesh, Richard G., Kathy E. Giusti, Robert S. Huckman, and Julia Kelley. "Intermountain Healthcare: Pursuing Precision Medicine." Harvard Business School Case 818-018, September 2017. (Revised February 2023.)
- 21 Jan 2014
- First Look
First Look: January 21
out its Genetics Diagnostic Lab into a fully commercial entity. Claritas offered over 100 genomic tests to detect a range of conditions, including autism and intellectual disabilities, and was developing new... View Details
Keywords: Sean Silverthorne
- 13 Jan 2009
- First Look
First Look: January 13, 2009
structurally attractive for soft drink firms, and b) if so, how can Pepsi best "catch-up" with Coca-Cola in a given market. Purchase this case: http://harvardbusinessonline.hbsp.harvard.edu/ b01/en/common/item_detail.jhtml?id=709451 Diagnostic View Details
Keywords: Martha Lagace
- 29 May 2001
- Research & Ideas
Genomics: Can We Start Making Money Now?
has only about 30,000 genes—far fewer than was previously believed. What's more, the genetic difference between people, indeed, between people and animals, is relatively small. Genomics is the most destructive force in the history of... View Details
Keywords: by Sean Silverthorne
- 12 Nov 2015
- Research & Ideas
Can Consumers be Trusted with Their Own Health Care?
and a profile that varies by situation and according to the patient’s life stage.” Patient Empowerment Taken Too Far? As an example of patient empowerment—and a glimpse at its potential problems—Quelch talked about taking the 23andMe test, a saliva-based... View Details
- 03 Mar 2015
- First Look
First Look: March 3
we call entrepreneurial beacons. We argue that the actions or outcomes of salient organizations attract and motivate entrepreneurs, thus increasing the rate of foundings. To test this logic, we examine the impact of the Yale University... View Details
Keywords: Sean Silverthorne
- 02 Apr 2013
- First Look
First Look: April 2
Publications 2006 Nature Reviews Beyond Magic Bullets: True Innovation in Health Care By: Narayan, Vaibhav A., Marco Mohwinckel, Gary Pisano, Michael Yang, and Husseini Manji Abstract—The molecular medicine revolution-based on advances in fields such as View Details
Keywords: Sean Silverthorne
- 07 Nov 2017
- First Look
New Research and Ideas: November 7, 2017
targeted therapies administered through IPG extended patient lifespans but increased overall costs. Now, in mid-2017, IPG is undergoing a major transition as it prepares to outsource the bulk of its genomic View Details
Keywords: Carmen Nobel
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
question—it’s clear.” Simply put, inefficiencies in the development of precision medicine can best be addressed by a business-analysis approach. With the mapping of the human genome completed 15 years ago, the sci-fi concept of using a... View Details
- 15 Feb 2000
- Research & Ideas
The Right Connections
From genome research to e-commerce, new ventures are popping up everywhere, competing for the cash needed to turn them into successful enterprises. But when vying against others in industries where high uncertainty, long development... View Details
Keywords: by Judith A. Ross
- 15 Jun 2016
- Research & Ideas
These VC Partners May Make Your Firm Less Innovative
when VC firm Mohr Davidow made an investment in Navigenics, a direct competitor to personal genomics company 23andMe, a startup it had invested in previously. A year later, a similar case occurred when Andreesen Horowitz cut its... View Details
- 18 Apr 2019
- Research & Ideas
Open Innovation Contestants Build AI-Based Cancer Tool
for Google, etc. AI is already being used as an adjunct to diagnosis in some settings. However, the bar for US Food & Drug Administration approval for a diagnostic test is appropriately high, and “products” will need to meet this bar... View Details
- 10 Jan 2012
- First Look
First Look: January 10
a greater level of discretion to choose their interaction partners. Therefore, we expect to observe more homophilous interactions within these structures than across their boundaries. We test this argument using a dataset consisting of... View Details
Keywords: Sean Silverthorne
- 20 Oct 2009
- First Look
First Look: October 20
and test an empirical framework which allows us to separate selection from treatment effects of large shareholders. Individual blockholders tend to hold blocks in public firms located close to where they reside. Using this empirical... View Details
Keywords: Martha Lagace